EU and US could reach trade deal this weekend - Reuters
SANTA CLARA, Calif. - Agilent Technologies Inc. (NYSE: A), a global leader in analytical and clinical laboratory technologies with a market capitalization of $32.35 billion, announced today the election of Pascal Soriot and Judy Gawlik Brown to its Board of Directors, effective immediately. According to InvestingPro analysis, the company maintains a GOOD financial health score, reflecting its strong market position.
Pascal Soriot, the CEO of AstraZeneca, brings a wealth of experience from his tenure leading a major pharmaceutical company. Since 2012, Soriot has been at the helm of AstraZeneca, overseeing its transformation and growth. His career has also included significant roles at Genentech and Roche, with leadership positions spanning multiple continents including Australia, Europe, Japan, and the United States.
Judy Gawlik Brown, founder and CEO of Downtown Advisory, offers extensive financial and strategic expertise in the life-sciences and consumer-health industries. Her background includes serving as Chief Financial Officer of Perrigo Company and holding senior positions at Amgen. Brown’s international experience is further highlighted by her roles in Germany and Italy.
The appointments coincide with the planned retirement of long-serving board member Heidi Kunz, who steps down after more than two decades with Agilent. Kunz played a pivotal role in guiding the company from its early days following its spin-off to its current status as an industry leader.
Agilent’s President and CEO, Padraig McDonnell, expressed confidence that the new board members’ expertise will be invaluable, particularly as the company embarks on its three-year "Ignite Transformation" initiative. Koh Boon Hwee, chair of the Agilent Board, echoed this sentiment, emphasizing the benefits their experience will bring to shareholders and the ongoing refreshment of the Board.
The company, which generated $6.53 billion in revenue in the last twelve months and employs approximately 18,000 people worldwide, is known for providing innovative solutions and trusted insights in the scientific community. InvestingPro data shows the company has maintained dividend payments for 14 consecutive years, with its current ratio of 2.2 indicating strong financial stability. Investors can access detailed analysis and 8 additional key insights through InvestingPro’s comprehensive research report.The company is scheduled to report its next earnings on May 28, 2025, providing investors an opportunity to assess its continued growth trajectory. For those seeking deeper insights into Agilent’s financial health and future prospects, InvestingPro offers extensive analysis and valuation metrics as part of its coverage of over 1,400 US equities.
This announcement is based on a press release statement from Agilent Technologies Inc. and marks a strategic enhancement of its Board as the company continues to focus on growth and innovation in the life sciences sector.
In other recent news, New Found Gold Corp. announced the commencement of its 2025 work program on the Queensway Gold Project, focusing on drilling, geological mapping, and sampling to expand its resource base. The company also revealed its participation in several North American conferences, including the Canaccord Genuity Global Metals and Mining Conference, as part of its strategy to engage with investors and industry stakeholders. Additionally, New Found Gold Corp. has issued new stock options, although specific details were not disclosed. Meanwhile, Agilent Technologies received European IVDR certification for its PD-L1 IHC 22C3 pharmDx assay, which is now approved as a Companion Diagnostic for certain cancer therapies. This certification will enable broader patient access to targeted immunotherapies across Europe. In analyst updates, Jefferies maintained a Hold rating on Agilent Technologies but lowered its price target from $135 to $116, reflecting a more conservative market valuation. Furthermore, Agilent announced the upcoming resignation of board member Heidi Kunz, effective May 21, 2025, with no disagreements cited. The company expressed gratitude for Kunz’s contributions and assured investors of continued strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.